Aberrant DNA methylation of calcitonin receptor in Fabry patients treated with enzyme replacement therapy

Keywords:
Fabry disease
DNA-methylation
Enzyme replacement therapy
Hypoxia inducing factor-1 alpha
Calcitonin receptor

Fabry disease is as a result of a deficiency of the enzyme alpha-galactosidase A which leads to a gradual lysosomal accumulation of globotriaosylceramide (GB3) in cells of the body. Neuropathic pain is one of the prominent symptoms of Fabry disease in the initial stages of the disease [1,2,3], and a possible mechanism involves the release of inflammatory molecules such as calcitonin gene related peptide (CGRP) which activates both calcitonin receptor-like receptor (CRLR) and calcitonin receptor (CALCR) on cell membranes in target tissues, generating signals that regulate various functions within the cell such as neuropathic pain. The involvement of CGRP and CGLR receptors in pain transmission and modulation in central and peripheral nervous systems has been demonstrated in several studies and they appear to play an essential role in peripheral inflammation and development of neuropathic pain [4,5]. While the mechanism of symptom reduction through enzyme replacement therapy (ERT) is not known [6,7], an emerging evidence suggests that DNA methylation changes can affect important CpG (cytosine phosphodiester bond guanine) sites for pain hypersensitivity in neuropathic pain [8].

We therefore carried out a retrospective investigation of the DNA methylation status of the promoter region of the calcitonin receptor in Fabry patients (6 non-ERT treated and 3 ERT treated) and 6 healthy controls respectively, using bisulphite modified DNA isolated from blood leukocytes, methylation specific PCR, high resolution melting, and sequencing as previously described [9]. The inclusion criteria for Fabry patients before and after ERT, thus enabling a concrete statement about the CALCR methylation could be an epigenetic biomarker of ERT. However, it also needs to be considered that ERT is mainly intended for patients with progressive disease and extensive clinical presentation [10]. Therefore it could be argued that the CALCR methylation on both alleles in ERT treated Fabry patients rather indicates the severity of disease manifestation than therapy, in which case the CALCR methylation could be an epigenetic biomarker for disease severity. In order to systematically and precisely investigate these possibilities, a design of a prospective study of more Fabry patients before and after ERT for a methylation at −78504 CpG in the promoter region of CALCR gene would be necessary. Therefore, it would be possible to directly compare the methylation status of CALCR of the same Fabry patients before and after ERT, thus enabling a concrete statement about the significance of a CALCR methylation at −78504 CpG as an epigenetic biomarker.

Conflict of interest

The authors do not have any conflict of interests.

Acknowledgment

We wish to thank David Kasper for providing the patient samples. This project was supported by the Department of Pediatrics, University of Vienna Medical School, Vienna, Austria (Apothekengeld/Kotenstell:370110).

References

[1] Y.A. Zarate, R.J. Hopkin, Fabry’s disease, Lancet 372 (2008) 1427–1435.
[2] A. Tuttolomondo, R. Pecoraro, I. Simoniotta, et al., Neurological complications of Anderson–Fabry disease, Curr. Pharm. Des. 19 (2013) 6014–6030.
[3] A.T. Möller, T.S. Jensen, Neurological manifestations in Fabry’s disease, Nat. Clin. Pract. Neurol. 3 (2007) 95–106.
[4] M. Zaidi, L.H. Breimer, I. Machnitzky, Biology of peptides from the calcitonin genes, Q. J. Exp. Physiol. 72 (4) (1987) 371–408.
[5] L.C. Yu, J.F. Hou, F.H. Fu, Y.X. Zhang, Roles of calcitonin gene-related peptide and its receptors in pain-related behavioral responses in the central nervous system, Neurosci. Biobehav. Rev. 33 (2009) 1185–1191.
Fig. 1. Panel A: Demethylation at $-78504$ CpG on both alleles. Panel B: Total methylation at $-78504$ CpG on both alleles. Panel C: Partial methylation at $-78504$ CpG on one allele. Panel D: High resolution melting shows methylation peak shifts indicating different degrees of methylation at $-78504$ CpG.